Arcus Biosciences, Inc.
RCUS · NYSE
Analyst ratings
buy · 9 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| May 18, 2026 | Truist Securities | Assumes | Buy | $35.00 |
| May 11, 2026 | Morgan Stanley | Maintains | Equal-Weight | $22.00 |
| May 7, 2026 | Goldman Sachs | Maintains | Buy | $34.00 |
| April 2, 2026 | Wedbush | Maintains | Outperform | $41.00 |
| March 5, 2026 | Citigroup | Maintains | Buy | $45.00 |
| March 2, 2026 | Leerink Partners | Maintains | Outperform | $49.00 |
| March 2, 2026 | HC Wainwright & Co. | Reiterates | Buy | $32.00 |
| February 12, 2026 | Wells Fargo | Downgrades | Equal-Weight | $23.00 |
| January 13, 2026 | Goldman Sachs | Upgrades | Buy | $28.00 |
| January 8, 2026 | Morgan Stanley | Downgrades | Equal-Weight | $20.00 |
| December 12, 2025 | HC Wainwright & Co. | Maintains | Buy | $32.00 |
| November 28, 2025 | B of A Securities | Maintains | Neutral | $26.00 |
| October 30, 2025 | Goldman Sachs | Maintains | Neutral | $16.00 |
| October 29, 2025 | Citigroup | Maintains | Buy | $56.00 |
| October 29, 2025 | HC Wainwright & Co. | Maintains | Buy | $28.00 |
| October 20, 2025 | Wells Fargo | Maintains | Overweight | $29.00 |
| October 13, 2025 | Citigroup | Maintains | Buy | $54.00 |
| October 7, 2025 | Truist Securities | Reiterates | Buy | $39.00 |
Pipeline potential vs. persistent financial underperformance
Arcus is forecast to grow earnings and revenue by 30.5% and 36.1% per annum respectively, and Goldman Sachs raised its price target to $34 with a Buy rating, while Leerink Partners set a $47 target — reflecting strong confidence in the company's drug pipeline and upcoming clinical milestones.
Arcus posted a weaker-than-expected quarter with EPS of -$1.02, missing Wall Street estimates, and quarterly revenue fell 39.29% year-over-year. The company's financial score ranks 314 out of 386 in its industry, signaling weak operating efficiency and deteriorating fundamentals.
Gilead collaboration and casdatifan strategic value
Analysts at Wells Fargo initiated coverage with an Overweight rating, citing anticipated success for casdatifan in clear cell renal cell carcinoma and the strategic value of the Gilead and AstraZeneca collaborations as key catalysts for long-term value creation.
Despite partnership activity, Wall Street Zen downgraded Arcus to a Sell rating, and BTIG slashed its price target from $70 to $43, reflecting skepticism about whether the collaboration revenues and pipeline progress can offset the company's ongoing losses and execution risks.
Near-term stock valuation and price target divergence
The consensus analyst rating remains Moderate Buy with an average price target of $35.10, and Wedbush raised its target to $41 with an Outperform rating. Technical indicators including the MA20, MA50, and MA200 all signal a buy on the weekly chart, supporting a strong broader uptrend.
The stock carries a Hold rating with a $30 target from some analysts, and overbought RSI readings of 73.28 alongside a Stochastic RSI at 94.95 signal short-term price exhaustion. RCUS has also pulled back over 6% in a single session, raising concerns about near-term downside.